Myo-inositol and Melatonin in Pre-menopausal Women

NCT ID: NCT01115127

Last Updated: 2012-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether myo-inositol and melatonin, or myo-inositol alone, or melatonin alone, are effective in normalizing irregular bleeding and anovulatory cycles in pre-menopausal women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Melatonin has produced a remarkable significant improvement of thyroid function, positive changes of gonadotropins towards reduced levels, and in some women a re-acquisition of normal menstrual cycle. Furthermore, an abrogation of menopause-related depression, amelioration of hot-flashes and improvement of quality and duration of sleep has been reported.

Myo-inositol is involved in several aspects of human reproduction. Elevated concentrations of myo-inositol in human follicular fluids appear to play a positive function in follicular maturity and provide a marker of good quality oocytes. Nevertheless its positive role in PCOS women is a consequence of a defect in the insulin signalling pathway (inositol-containing phosphoglycan mediators) that seems to be primarily implicated in the pathogenesis of insulin resistance

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-menopausal Irregular Cycles and Bleedings

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

myo-inositol

30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.

Group Type ACTIVE_COMPARATOR

myo-inositol

Intervention Type DIETARY_SUPPLEMENT

30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.

melatonin

30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months

Group Type ACTIVE_COMPARATOR

melatonin

Intervention Type DIETARY_SUPPLEMENT

30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months

melatonin plus myo-inositol

30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months

Group Type ACTIVE_COMPARATOR

melatonin plus myo-inositol

Intervention Type DIETARY_SUPPLEMENT

30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

melatonin

30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months

Intervention Type DIETARY_SUPPLEMENT

myo-inositol

30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.

Intervention Type DIETARY_SUPPLEMENT

melatonin plus myo-inositol

30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all pre-menopausal women with irregular cycles and bleedings

Exclusion Criteria

* pre-menopausal women who take hormonal drugs
Minimum Eligible Age

40 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Messina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rosario D'anna

Myo-inositol and melatonin in menopausal transition.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rosario D'Anna, MD

Role: PRINCIPAL_INVESTIGATOR

University of Messina

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital

Messina, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Myo-Mela-2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Soy Isoflavones on Menopausal Hot Flashes
NCT00179556 COMPLETED PHASE2/PHASE3